EGFR and head and neck squamous cell carcinoma: Until recently, the standard of care (SOC) for patients with recurrent or metastatic HNSCC, incurable by concurrent chemoradiation and surgery, was cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody, in combination with a platinum agent and fluorouracil.